5-甲基苯并二氢吡喃-4-酮 | 18385-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 5-甲基苯并二氢吡喃-4-酮
• 中文别名: 2,3-二氢-5-甲基-4H-1-苯并吡喃-4-酮
• 英文名称: 5-methyl-2,3-dihydrochromen-4-one
• 英文别名: 5-methyl-2,3-dihydro-4H-1-benzopyran-4-one；5-methylchroman-4-one；5-Methyl-chroman-4-on
• CAS: 18385-68-7
• 化学式: C₁₀H₁₀O₂
• 分子量: 162.188
• InChiKey: ZFVQMWINGWSVPO-UHFFFAOYSA-N

物化性质

• 沸点：
  302.6±42.0 °C(Predicted)
• 密度：
  1.157

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319

反应信息

• 作为反应物：
  描述：

  5-甲基苯并二氢吡喃-4-酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以62 %的产率得到5-甲基-苯并二氢吡喃-4-醇
  参考文献：
  名称：

  从基于片段的 NMR 筛选中开发变构 NIK 配体

  摘要：

  NF-κB 诱导激酶 （NIK） 对于诱导许多免疫反应至关重要，因此，NIK 失调与各种炎症性疾病和癌症有关。NIK 一直被作为潜在的治疗靶点进行研究，并且已经报道了结合 NIK 上正构位点的小分子抑制剂。然而，尽管确定了化学物质，但 NIK 抑制剂尚未进入临床。为了使用基于片段的 NMR 筛选方法开发变构 NIK 配体，我们报告了一系列变构、片段大小的 NIK 配体的鉴定和开发，这些配体与微摩尔效力和良好的配体效率结合。

  DOI：

  10.1021/acsmedchemlett.3c00429
• 作为产物：
  描述：

  3-间甲苯氧基丙酸 在 polyphosphoric acid 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以17 g的产率得到5-甲基苯并二氢吡喃-4-酮
  参考文献：
  名称：

  一种含氧杂环化合物的制备方法

  摘要：

  本发明公开了一种含氧杂环化合物4‑羟基‑5‑甲基‑3,4‑二氢‑2H‑色烯‑4‑羧酸的制备方法，以4‑甲基苯酚为起始原料，经过缩合、关环、氰化、脱TMS、水解得到目标产物，该化合物是重要的医药中间体。

  公开号：

  CN106632192A

文献信息

• [EN] APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE KINASE 1 (ASK 1) DE RÉGULATION DU SIGNAL DE L'APOPTOSE
  申请人：SIDECAR THERAPEUTICS INC

  公开号：WO2019070742A1

  公开（公告）日：2019-04-11

  Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with ASK1 activity.

  本文描述了ASK1抑制剂，制备这类化合物的方法，包含这类化合物的药物组合物和药物，以及使用这类化合物治疗与ASK1活性相关的疾病、疾病或疾病的方法。
• Acid activated montmorillonite K-10 mediated intramolecular acylation: Simple and convenient synthesis of 4-chromanones
  作者：Ayisha F. Begum、Kalpattu K. Balasubramanian、Bhagavathy Shanmugasundaram

  DOI：10.1016/j.tetlet.2021.153372

  日期：2021.10

  in toluene under reflux for 30–45 min in good to excellent yields. Phenyl ring bearing various substituents at the ortho, meta, para positions undergo this cyclization reaction. This method involves simple work up and amenable for large scale preparations. The heterogeneous acid treated catalyst can be regenerated and used for up to three cycles with minimum loss of activity.

  3-芳氧基丙酸在 AA.Mont.K-10 的存在下在甲苯中回流 30-45 分钟，以良好到极好的产率进行分子内环化。在邻位、间位、对位带有各种取代基的苯基环会发生这种环化反应。该方法涉及简单的后处理，适用于大规模制备。经多相酸处理的催化剂可以再生并最多使用三个循环，而活性损失最小。
• Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists
  申请人：Koike Hiroki

  公开号：US20080214519A1

  公开（公告）日：2008-09-04

  This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 , R 7 , R 8 and R 9 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中：A、B、X、R1、R2、R3、R4、R5和R6、R7、R8和R9分别如本文所述或其药学上可接受的盐，以及包含这种化合物的组合物以及在治疗由酸泵拮抗活性介导的疾病，如但不限于胃肠疾病、胃食管疾病、胃食管反流病（GERD）、消化性溃疡、胃溃疡、十二指肠溃疡、NSAID诱导性溃疡、胃炎、幽门螺杆菌感染、消化不良、功能性消化不良、佐林格-埃里森综合症、非侵蚀性反流性疾病（NERD）、内脏疼痛、心口灼热、恶心、食管炎、吞咽困难、多口水、气道障碍或哮喘等疾病中使用这种化合物的用途。
• Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles
  申请人：Galley Guido

  公开号：US20070197620A1

  公开（公告）日：2007-08-23

  The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R 1 , R 2 , Q, W, X, Y, m, and n are as defined in the specification d or not; and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗选自抑郁症、焦虑症、双相情感障碍、注意力缺陷多动症、压力相关疾病、精神疾病如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和同化障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的公式为R1，R2，Q，W，X，Y，m和n如规范中所定义的，或不定义；以及它们的药物活性盐，外消旋混合物，对映异构体，光学异构体和互变异构体形式。本发明还涉及公式I的新化合物，包含它们的组合物以及其制备方法。
• METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20120071506A1

  公开（公告）日：2012-03-22

  The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R 1 , R 2 , Q, W, X, Y, m, and n are as defined in the specification, and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗选自抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、与压力有关的障碍、精神病性障碍如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管障碍的方法，包括向个体施用公式I化合物的治疗有效量，其中R1、R2、Q、W、X、Y、m和n在说明书中定义，以及它们的药物活性盐、混合物、对映体、光学异构体和互变异构体。本发明还涉及公式I的新化合物、含有它们的组合物以及其制备方法。